HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

9th Edition of International Conference on

Neurology and Neurological Disorders

June 20-22, 2024 | Paris, France

Neurology 2023

Lloyd L Tran

Speaker at Neurology and Neurological Disorders 2023 - Lloyd L Tran
Biomed Industries, Inc., United States
Title : Neurogenesis Hypothesis with a Case Study-Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease

Abstract:

In the hippocampus, new neurons are generated throughout life via a process called adult hippocampal neurogenesis (AHN). In mild cognitive impairment (MCI) and mild to moderate AD (early AD), AHN is reduced suggesting that AHN impairment compromises hippocampal function. Accordingly, augmenting AHN could help prevent or slow cognitive decline in MCI and early AD.

NA-831 is a small drug molecule, which activates synaptic AMPA receptors, and increases the expression of BDNF (brain derived neurotrophic factor). BDNF is crucial in synaptic plasticity, learning and memory formation in the hippocampus. NA-831 restores neurogenesis by increasing the number of DCX+PCNA+ neuroblast cells.

A randomized clinical trial of NA-831 was conducted in 32 patients with MCI, who received 10 mg of NA- 831 or placebo orally per day; and 24 patients with mild and moderate AD, who received 30 mg of NA-831 or placebo orally per day for 24 weeks.

RESULTS: NA-831 provided a significant delay in cognitive decline in MCI as measured by ADAS-Cog-13, an average score difference of 3.4 compared to placebo (p = 0.01; ITT) after 24 weeks of treatment.

Similarly, NA-831 delayed cognitive decline in early AD, an average score difference of 4.1 com-pared to placebo (p = 0.001; ITT). CIBIC-Plus showed 78 % of the study participants receiving NA-831 improved (p = 0.01; ITT).

NA-831 was well-tolerated at 30 mg/day for 24 weeks, and no serious adverse events were observed.

CONCLUSION: The Phase 2A results of NA-831 support the viability of Neurogenesis Hypothesis as an alternative approach to the Amyloid Hypothesis. Details of these Phase 2A clinical trials and the Neurogenesis Hypothesis will be presented and discussed.

Audience Take Away

  • Introduce the Neurogenesis Hypothesis as an alternative approach to the Amyloid Hypothesis
  • Show the Phase 2A clinical results of a new drug NA-831 for the treatment of Alzheimer’s disease
  • The Phase 2A of NA-831 supports the viability of the Neurogenesis Hypothesis
  • The presentation can inspire researchers to look into Neurogenesis Hypothesis that can possibly replace the Amyloid Hypothesis as the guidance for drug development

Biography:

Lloyd is a scientist with 25-year experience in drug development. He is an inventor with a number of patents in drug therapeutics in the treatment of neurological diseases. Lloyd serves as the chairman and Chief Scientific Officer of Biomed Industries, Inc. Lloyd was the discoverer of NA-831, which has completed the Phase 2 for the treatment of Alzheimer’s Disease. In his early career, he was employed as a research scientist at G.D. Searle, (a subsidiary of Pfizer), and was the director of R&D at Biomed Pharmaceuticals. Lloyd graduated with a BSc (Honours) and completed a PhD in medicinal chemistry at University of Otago and Wellington University of New Zealand.

Watsapp